| A prognostic score for advanced Hodgkin's disease D Hasenclever, V Diehl, JO Armitage, D Assouline, M Björkholm, ... New England Journal of Medicine 339 (21), 1506-1514, 1998 | 2323 | 1998 |
| Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease … N Schmitz, B Pfistner, M Sextro, M Sieber, AM Carella, M Haenel, ... The Lancet 359 (9323), 2065-2071, 2002 | 1348 | 2002 |
| A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling M Hummel, S Bentink, H Berger, W Klapper, S Wessendorf, TFE Barth, ... New England Journal of Medicine 354 (23), 2419-2430, 2006 | 1212 | 2006 |
| Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease V Diehl, J Franklin, M Pfreundschuh, B Lathan, U Paulus, D Hasenclever, ... New England Journal of Medicine 348 (24), 2386-2395, 2003 | 1168 | 2003 |
| Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL M Pfreundschuh, L Trümper, M Kloess, R Schmits, AC Feller, C Rübe, ... Blood 104 (3), 634-641, 2004 | 901 | 2004 |
| Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era M Ziepert, D Hasenclever, E Kuhnt, B Glass, N Schmitz, M Pfreundschuh, ... Journal of clinical oncology 28 (14), 2373-2380, 2010 | 773 | 2010 |
| A multicenter trial of remote ischemic preconditioning for heart surgery P Meybohm, B Bein, O Brosteanu, J Cremer, M Gruenewald, C Stoppe, ... New England Journal of Medicine 373 (15), 1397-1407, 2015 | 731 | 2015 |
| Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study A Engert, V Diehl, J Franklin, A Lohri, B Dörken, WD Ludwig, P Koch, ... Journal of Clinical Oncology 27 (27), 4548-4554, 2009 | 647 | 2009 |
| Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL … M Pfreundschuh, L Trümper, M Kloess, R Schmits, AC Feller, C Rudolph, ... Blood 104 (3), 626-633, 2004 | 618 | 2004 |
| Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage … A Engert, P Schiller, A Josting, R Herrmann, P Koch, M Sieber, ... Journal of Clinical Oncology 21 (19), 3601-3608, 2003 | 573 | 2003 |
| Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma … A Engert, J Franklin, HT Eich, C Brillant, S Sehlen, C Cartoni, R Herrmann, ... Journal of Clinical Oncology 25 (23), 3495-3502, 2007 | 345 | 2007 |
| Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised … N Schmitz, A Bacigalupo, D Hasenclever, A Nagler, E Gluckman, P Clark, ... Bone marrow transplantation 21 (10), 995-1003, 1998 | 325 | 1998 |
| Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study C Mauz-Körholz, D Hasenclever, W Dörffel, K Ruschke, T Pelz, A Voigt, ... Journal of clinical oncology 28 (23), 3680-3686, 2010 | 308 | 2010 |
| Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults I Salaverria, C Philipp, I Oschlies, CW Kohler, M Kreuz, M Szczepanowski, ... Blood, The Journal of the American Society of Hematology 118 (1), 139-147, 2011 | 306 | 2011 |
| Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia N Schmitz, M Beksac, D Hasenclever, A Bacigalupo, T Ruutu, A Nagler, ... Blood, The Journal of the American Society of Hematology 100 (3), 761-767, 2002 | 305 | 2002 |
| Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. M Loeffler, O Brosteanu, D Hasenclever, M Sextro, D Assouline, ... Journal of Clinical Oncology 16 (3), 818-829, 1998 | 282 | 1998 |
| BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of … V Diehl, J Franklin, D Hasenclever, H Tesch, M Pfreundschuh, B Lathan, ... Journal of Clinical Oncology 16 (12), 3810-3821, 1998 | 267 | 1998 |
| ErbB-3 predicts survival in ovarian cancer B Tanner, D Hasenclever, K Stern, W Schormann, M Bezler, M Hermes, ... Journal of clinical oncology 24 (26), 4317-4323, 2006 | 260 | 2006 |
| The role of HPV RNA transcription, immune response‐related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and … G Wichmann, M Rosolowski, K Krohn, M Kreuz, A Boehm, A Reiche, ... International journal of cancer 137 (12), 2846-2857, 2015 | 215 | 2015 |
| Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma W Klapper, M Kreuz, CW Kohler, B Burkhardt, M Szczepanowski, ... Blood, The Journal of the American Society of Hematology 119 (8), 1882-1887, 2012 | 208 | 2012 |
